Camille VEREBI

Dr. Camille VEREBI

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2023 in Journal of Assisted Reproduction and Genetics
Verified
Journal Article
Closed access
PDF file
PJPénélope Jordan
Pénélope Jordan
CVCamille VEREBI
Camille VEREBI
SPSandrine Perol
Sandrine Perol
SGSarah Grotto
Sarah Grotto
CFCorinne Fouveaut
Corinne Fouveaut
TBThierry Bienvenu
Thierry Bienvenu

24 April 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MPMathilde Pacault
Mathilde Pacault
CVCamille VEREBI
Camille VEREBI
MCMagali Champion
Magali Champion
LOLucie Orhant
Lucie Orhant
APAlexandre Perrier
Alexandre Perrier
JNJuliette Nectoux
Juliette Nectoux
Non-invasive prenatal diagnosis of single-gene disorders (SGD-NIPD) has been widely accepted, but is mostly limited to the exclusion of either paternal or de novo mutations. Indeed, it is still difficult to infer the inheritance of the maternal allele from cell-free DNA (cfDNA) analysis. Based on the study of maternal haplotype imbalance in cfDNA, relative haplotype dosage (RHDO) was developed to address this challenge. Although RHDO has been shown to be reliable, robust control of statistical error and explicit delineation of critical parameters for assessing the quality of the analysis have not been fully addressed. We present here a universal and adaptable enhanced-RHDO (eRHDO) procedure through an automated bioinformatics pipeline with a didactic visualization of the results, aiming to be applied for any SGD-NIPD in routine care. A training cohort of 43 families carrying CFTR, NF1, DMD, or F8 mutations allowed the characterization and optimal setting of several adjustable data variables, such as minimum sequencing depth, type 1 and type 2 statistical errors, as well as the quality assessment of intermediate steps and final results by block score and concordance score. Validation was successfully performed on a test cohort of 56 pregnancies. Finally, computer simulations were used to estimate the effect of fetal-fraction, sequencing depth and number of informative SNPs on the quality of results. Our workflow proved to be robust, as we obtained conclusive and correctly inferred fetal genotypes in 94.9% of cases, with no false-negative or false-positive results. By standardizing data generation and analysis, we fully describe a turnkey protocol for laboratories wishing to offer eRHDO-based non-invasive prenatal diagnosis for single-gene disorders as an alternative to conventional prenatal diagnosis.

25 May 2023 in European Journal of Neurology
Verified
Journal Article
Open access
EBEdouard Berling
Edouard Berling
CVCamille VEREBI
Camille VEREBI
NVNadia Venturelli
Nadia Venturelli
SVStéphane Vassilopoulos
Stéphane Vassilopoulos
ABAnthony Béhin
Anthony Béhin
TSTanya Stojkovic
Tanya Stojkovic
Background and purpose: CAV3 gene mutations, mostly inherited as an autosomal dominant trait, cause various skeletal muscle diseases. Clinical presentations encompass proximal myopathy, distal myopathy, or isolated persistent high creatine kinase (CK) with a major overlapping phenotype.Methods: Twenty‐three patients with CAV3 symptomatic mutations, from 16 different families, were included in a retrospective cohort. Mean follow‐up duration was 24.2 ± 15.0 years. Clinical and functional data were collected during the follow‐up. The results of muscle imaging, electroneuromyography, muscle histopathology, immunohistochemistry, and caveolin‐3 Western blot analysis were also compiled.Results: Exercise intolerance was the most common phenotype (52%). Eighty percent of patients had calf hypertrophy, and only 65% of patients presented rippling. One patient presented initially with camptocormia. A walking aid was required in only two patients. Electroneuromyography was mostly normal. CK level was elevated in all patients. No patient had cardiac or respiratory impairment. Muscle imaging showed fatty involvement of semimembranosus, semitendinosus, rectus femoris, biceps brachialis, and spinal muscles. Almost all (87%) of the biopsies were abnormal but without any specific pattern. Whereas a quarter of patients had normal caveolin‐3 immunohistochemistry results, Western blots disclosed a reduced amount of the protein. We report nine mutations, including four not previously described. No phenotype–genotype correlation was evidenced.Conclusions: Caveolinopathy has diverse clinical, muscle imaging, and histological presentations but often has limited functional impact. Mild forms of the disease, an atypical phenotype, and normal caveolin‐3 immunostaining are pitfalls leading to misdiagnosis.

26 December 2024 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
LGLaurène Gérard
Laurène Gérard
MDMégane Delourme
Mégane Delourme
CTCharlotte Tardy
Charlotte Tardy
BGBenjamin Ganne
Benjamin Ganne
PPPierre Perrin
Pierre Perrin
FMFrederique Magdinier
Frederique Magdinier

Verified
Journal Article
Open access
PDF file
SBSophie Brouillet
Sophie Brouillet
SMSandie Mereuze
Sandie Mereuze
NRNoemie Ranisavljevic
Noemie Ranisavljevic
CCClaire Chauveau
Claire Chauveau
SHSamir Hamamah
Samir Hamamah
MWMarjolaine WILLEMS
Marjolaine WILLEMS
Preimplantation genetic testing (PGT) is widely used to select unaffected embryos, increasing the odds of having a healthy baby. During the last few decades, it was accepted that monozygotic dichorionic diamniotic twin pregnancies occurred from the embryo splitting before Day 3 postfertilization according to Corner’s dogma. Hence, the occurrence of a dichorionic diamniotic twin pregnancy after a single blastocyst transfer was considered a dizygotic pregnancy resulting from blastocyst transfer and concurrent natural fertilization. In our study, we have provided for the first time molecular proof that a single blastocyst transfer can result in a monozygotic dichorionic diamniotic twin pregnancy, invalidating Corner’s dogma. In this case, we recommend systematically assessing the genetic status of dichorionic twins after single blastocyst transfer using prenatal diagnosis to exclude the risk from a potential concurrent spontaneous pregnancy and to ensure that both fetuses are unaffected. To achieve this goal, we have developed here an innovative noninvasive prenatal diagnosis by exclusion of paternal variants with droplet digital PCR, maximizing the reliability of genetic diagnosis. Further multicentric prospective studies using genetic testing are now required to establish the rate of blastocyst splitting leading to dichorionic pregnancy in PGT and to identify the risk factors.

19 June 2024 in Journal of Genetic Counseling
Verified
Journal Article
Open access
CVCamille VEREBI
Camille VEREBI
VGVictor Gravrand
Victor Gravrand
TBThierry Bienvenu
Thierry Bienvenu
FLFrance Leturcq
France Leturcq
JNJuliette Nectoux
Juliette Nectoux
Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are the most common inherited neuromuscular diseases. Following the identification of a pathogenic causative variant in the DMD gene of a proband, potential carriers can be informed of their risk of having offspring with the disease. Germline mosaicism is a variant that is confined to the gonads that can be transmitted to offspring and is usually reported when a non‐carrier of a DMD pathogenic variant has two or more offspring carrying the variant in question. On average, one third of cases are the result of a de novo variant, and as DMD and BMD are prone to germline mosaicism, its inclusion in genetic counseling is mandatory. In this retrospective cohort study, we presented clinical data from an unpublished DMD/BMD cohort of 332 families with incidence of germline mosaicism in families with de novo transmission of 8.1%. This is also the first systematic literature review searching PubMed to provide an accurate assessment of the current literature on germline mosaicism in DMD and BMD, including 17 case reports and 20 original studies. The incidence of documented germline mosaicism in de novo event families ranged from 6.0 to 40%, with a mean of 8.3%. The estimated recurrence risk for mothers of a patient with a proven de novo causal variant ranged from 4.3 to 11%, with a mean of 5.8% for a male fetus. By providing an up‐to‐date and comprehensive overview of the literature, this review aims to improve our understanding of germline mosaicism in DMD and to promote the development of effective strategies and reliable data for occurrence risk assessment in genetic counseling of de novo event families.